目的探讨米非司酮治疗子宫肌瘤的临床效果。方法对于2007年3月至2008年9月收治的26例子宫肌瘤患者,分成两组,分别给予米非司酮组和促性腺激素释放激素激动剂,对治疗后子宫体积、肿瘤体积和肿瘤缩小范围进行研究。结果GnRH-a组治疗后,肌瘤体积均缩小70%以上;米非司酮组连续治疗后,肌瘤体积均缩小71.5%以上。结论两组差异无统计学意义,但米非司酮的不良反应较轻,停药后肌瘤复发率较低,更易于临床推广。 Objective To investigate the clinical efficacy of mifepristone in treating uterine fibroids. Methods Twenty-six patients with uterine fibroids who were treated from March 2007 to September 2008 were divided into two groups and treated with mifepristone and gonadotropin-releasing hormone agonist respectively. The uterine fibroids volume, tumor volume and tumor volume Narrow the scope for research. Results After treatment, the volume of fibroids in GnRH-a group was reduced by more than 70%. After continuous treatment with mifepristone group, the fibroids volume decreased by 71.5% or more. Conclusion There was no significant difference between the two groups, but the side effects of mifepristone were mild, and the relapse rate of fibroids was lower after stopping the drug treatment, which was easier to be popularized clinically.